Anixa Biosciences (ANIX) Competitors

Allogene Therapeutics (NASDAQ:ALLO) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Does the media prefer ALLO or ANIX?

In the previous week, Anixa Biosciences had 15 more articles in the media than Allogene Therapeutics. MarketBeat recorded 22 mentions for Anixa Biosciences and 7 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.13 beat Anixa Biosciences' score of 0.17 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anixa Biosciences	1 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Do analysts rate ALLO or ANIX?

Allogene Therapeutics currently has a consensus price target of $9.29, indicating a potential upside of 495.44%. Anixa Biosciences has a consensus price target of $9.00, indicating a potential upside of 192.21%. Given Allogene Therapeutics' higher probable upside, equities research analysts clearly believe Allogene Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Anixa Biosciences	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Does the MarketBeat Community favor ALLO or ANIX?

Allogene Therapeutics received 253 more outperform votes than Anixa Biosciences when rated by MarketBeat users. However, 75.61% of users gave Anixa Biosciences an outperform vote while only 65.89% of users gave Allogene Therapeutics an outperform vote.

Company	Underperform	Outperform
Allogene Therapeutics	Outperform Votes 284 65.89%	Underperform Votes 147 34.11%
Anixa Biosciences	Outperform Votes 31 75.61%	Underperform Votes 10 24.39%

Which has higher earnings & valuation, ALLO or ANIX?

Anixa Biosciences has higher revenue and earnings than Allogene Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$22K	15,406.06	-$327.27M	-$1.33	-1.17
Anixa Biosciences	$210K	472.22	-$12.55M	-$0.39	-7.90

Do institutionals & insiders believe in ALLO or ANIX?

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 24.3% of Allogene Therapeutics shares are held by insiders. Comparatively, 25.3% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility and risk, ALLO or ANIX?

Allogene Therapeutics has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Is ALLO or ANIX more profitable?

Allogene Therapeutics' return on equity of -52.13% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-52.13%	-41.29%
Anixa Biosciences	N/A	-58.55%	-53.29%

Summary

Allogene Therapeutics beats Anixa Biosciences on 10 of the 18 factors compared between the two stocks.